The abstract is read at the publisher; the summary is JClub's.
Thiolated recombinant human catalase (hCAT-SH) as a dry eye disease eye drop significantly improved corneal fluorescein staining in a first-in-human trial at 0.1 mg/mL versus placebo.
- Why it matters: Oxidative stress from excess reactive oxygen species is linked to dry eye disease progression, but no approved therapy directly eliminates ROS.
- What they did: The team engineered thiolated hCAT and tested activity, stability, mucin interaction, and ocular retention, then assessed efficacy and safety in mouse, rabbit, and rat models before a randomized, double-blind, placebo-controlled first-in-human study in 30 patients.
- The result: In patients, 0.1 mg/mL hCAT-SH reduced tear cytokine levels and corneal dendritic cell density versus placebo without treatment-related safety concerns, supporting further development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.